TerminatedPhase 1NCT04614636
FT538 in Subjects With Advanced Hematologic Malignancies
Studying Plasma cell leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fate Therapeutics
- Principal Investigator
- Fate Trial DisclosureFate Therapeutics, Inc
- Intervention
- FT538(drug)
- Enrollment
- 42 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2023
Study locations (8)
- Colorado Blood Cancer Institute, Denver, Colorado, United States
- University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
- Washington University, St Louis, Missouri, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, United States
- St. David's South Austin Medical Center, Austin, Texas, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Texas Transplant Institute, San Antonio, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04614636 on ClinicalTrials.govOther trials for Plasma cell leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07202091Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)Monash University
- RECRUITINGEARLY PHASE1NCT06718270a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell LeukemiaShanghai Changzheng Hospital
- RECRUITINGPHASE2NCT06140966Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple MyelomaUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT05979363A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell LeukemiaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT06045091To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCLHrain Biotechnology Co., Ltd.
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT05838131Study of CT071 Injection in RRMM or PPCLShanghai Changzheng Hospital
- RECRUITINGPHASE1NCT05759793A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaNanjing IASO Biotechnology Co., Ltd.
- RECRUITINGPHASE1NCT05528887Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological MalignanciesThe Affiliated People's Hospital of Ningbo University